Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome p450 inhibition and their method of use

A compound comprising formula (I):

• or a hydrate, solvate, enantiomer, diastereomer, pharmaceutically acceptable salt, prodrug or complex thereof, wherein
• Q is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl,
• R1a, R1b, R1c, R1d, and R1e are each independently selected from the group consisting of hydrogen, halogen, OH, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl, C1-6, optionally substituted alkoxy, —NR4aR4b, —NR5COR6, —CO2R6, —CO2NR4aR4b, —NHSO2R7, —SH, —SR7, SO2R7 and —SO2NHR6;
• R2a, R2b, R2c, R2d, R2e, R2f and R2g are each independently selected from the group consisting of hydrogen, halogen, OH, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl, C1-6 optionally substituted alkoxy, —NR4aR4b, —NR5COR6, —CO2R6, —CO2NR4aR4b, —NHSO2R7, —SH, —SR7, SO2R7 and —SO2NHR6;
• R3 is selected from a group consisting of —SO2R8, —C(O)NR9R10, —C(O)OR7,
• R4a and R4b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R5 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R6 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R7 is selected from the group consisting of optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R8 is selected from the group consisting of optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted C3-7 heterocyclyl;
• R9 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl,
• R10 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, and optionally substituted C1-6 branched alkyl;
• and
• R11a and R11b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted aryl, optionally substituted benzyl, —CH2OR6, and CH2 heteroaryl.

A compound selected from the group consisting of formula (X), formula (Xa) and any hydrate, solvate, enantiomer, diastereomer, pharmaceutically acceptable salt, prodrug or complex thereof, wherein

• R1a, R1b, R1c, R1d, and R1e are each independently selected from the group consisting of hydrogen, halogen, OH, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl, C1-6, optionally substituted alkoxy, —NR4aR4b, —NR5COR6, —CO2R6, —CO2NR4aR4b, —NHSO2R7, —SH, —SR7, SO2R7 and —SO2NHR6;
• R2a, R2b, R2c, R2d, R2e, R2f and R2g are each independently selected from the group consisting of hydrogen, halogen, OH, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, optionally substituted C3-7 cycloalkyl, optionally substituted C1-6 haloalkyl, C1-6 optionally substituted alkoxy, —NR4aR4b, —NR5COR6, —CO2R6, —CO2NR4aR4b, —NHSO2R7, —SH, —SR7, SO2R7 and —SO2NHR6;
• R4a and R4b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R5 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• R6 is selected from the group consisting of hydrogen, optionally substituted C1-6 linear alkyl, optionally substituted C1-6 branched alkyl, and optionally substituted C3-7 cycloalkyl;
• and
• R7 is selected from the group consisting of optionally substituted C1-6 linear alkyl, optionally substituted C1-6branched alkyl, and optionally substituted C3-7 cycloalkyl.